EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune and cellular determinants of response to HMA‐venetoclax regimens in acute myeloid leukemia

Alfredo Marchetti iD, Francesca Lazzaroni iD, Matteo Claudio Da Via', Marta Lionetti iD, Giulia Maggioni, Alessia Campagna iD, Denise Ventura, Giorgio A Croci iD, Alessio Marella, Akihiro Maeda, Antonio Matera iD, Emanuele Calvi und 16 weitere

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 13.10.2026. Verfasst von Alfredo Marchetti und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology-Oncology University of Milan Milan Italy. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Associazione Italiana per la Ricerca sul Cancro, Fondazione Umberto Veronesi.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypomethylating agents (HMAs) combined with Venetoclax have reshaped the therapeutic landscape of acute myeloid leukemia (AML), yet the biological determinants of response remain unclear. We integrated clinical and genomic profiling in 132 newly diagnosed or relapsed/refractory AML patients treated with HMA‐Venetoclax and performed single‐cell RNA sequencing and T cell receptor (TCR) profiling in 10 newly diagnosed cases to define cellular and immune correlates of response. Response rates and survival aligned with published data. DNA Sequencing confirmed the favorable impact of IDH2 and the poor prognosis of TP53 mutations. scRNA‐seq and TCR analysis showed that responders exhibited expansion of cytotoxic CD8 + T cells, increased TCR clonal diversity, and activation of antigen‐presentation pathways. Nonresponders displayed baseline inflammatory signaling, impaired myeloid maturation, and a suppressive microenvironment enriched in IDO1 + dendritic cells. Resistant AMLs showed stem‐like dedifferentiation and sustained EMT. LAG‐3 expression marked dysfunctional T cell states and emerged as a potential biomarker and therapeutic target.

Autor:innen und Institutionen

  • Department of Oncology and Hematology-Oncology University of Milan Milan Italy.
  • Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.
  • IRCCS Humanitas Research Hospital Rozzano Milan Italy.
  • Department of Pathophysiology and Transplantation University of Milan Milan Italy.
  • Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.
  • Clinical Pathology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy.

ORCID-Profile: Alfredo Marchetti, Francesca Lazzaroni, Marta Lionetti, Alessia Campagna, Giorgio A Croci, Antonio Matera, Matteo G D Porta, Mariarita Sciumè, Francesco Passamonti, Nicola S Fracchiolla, Niccolò Bolli

Förderung

  • European Research Council
  • Associazione Italiana per la Ricerca sul Cancro
  • Fondazione Umberto Veronesi

Zitieren

APA

Marchetti, A., Lazzaroni, F., Da Via', M. C., Lionetti, M., Maggioni, G., Campagna, A., Ventura, D., Croci, G. A., Marella, A., Maeda, A., Matera, A., Calvi, E., Scopetti, M., Viviani, F., Rampi, N., Bonometti, D., Benzoni, E., Zappa, M., Fabris, S., …, & Bolli, N. (2026). Immune and cellular determinants of response to HMA‐venetoclax regimens in acute myeloid leukemia. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70498

Vancouver

Marchetti A, Lazzaroni F, Da Via' MC, Lionetti M, Maggioni G, Campagna A, et al. Immune and cellular determinants of response to HMA‐venetoclax regimens in acute myeloid leukemia. HemaSphere. 2026;10(10). doi:10.1002/hem3.70498

BibTeX
@article{Marchetti2026,
  author = {Marchetti, Alfredo and Lazzaroni, Francesca and Da Via', Matteo Claudio and Lionetti, Marta and Maggioni, Giulia and Campagna, Alessia and Ventura, Denise and Croci, Giorgio A and Marella, Alessio and Maeda, Akihiro and Matera, Antonio and Calvi, Emanuele and Scopetti, Margherita and Viviani, Filippo and Rampi, Nicolò and Bonometti, Davide and Benzoni, Elena and Zappa, Manuela and Fabris, Sonia and Barbieri, Marzia and Pioggia, Stefania and Leoni, Claudia and Ricchiuti, Antony and Porta, Matteo G D and Sciumè, Mariarita and Passamonti, Francesco and Fracchiolla, Nicola S and Bolli, Niccolò},
  title = {Immune and cellular determinants of response to HMA‐venetoclax regimens in acute myeloid leukemia},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {10},
  doi = {10.1002/hem3.70498}
}
Kostenlos starten →